Kangpu Completed Bridging Clinical Study of KPG-818 in China

HEFEI, China, Sept. 20, 2024 /PRNewswire/ — Kangpu Biopharmaceuticals, a clinical-stage company based in Hefei, China, announced today that the Company has successfully completed a bridging clinical study of KPG-818 in healthy subjects in China.

The randomized, double-blind, placebo-controlled, and food effects (FE) study aimed to assess the safety and tolerability of multiple oral doses of KPG-818 in male and female healthy participants over a treatment period of 14 days and a follow-up period of 4 weeks, to characterize the single and multiple oral dose pharmacokinetics (PK) of KPG-818, and to select dosing regimens of KPG-818 for future clinical trials. A total of 30 participants were randomized to three escalating cohorts (n=10 each; 8 KPG-818, 2 placebo) receiving 0.15 mg, 0.6 mg, 2 mg or placebo once daily. In the FE cohort, 12 participants received single dose of 0.6 mg KPG-818 with and without food.

KPG-818 is well tolerated in healthy subjects. No serious adverse events (SAEs) were reported. The most common AEs were grades 1-2 of pruritus or rash.

Close to linear PK of KPG-818 was observed in the dosing range of 0.15 mg-2 mg.  Similar exposure was observed for KPG-818 under fed/fasted conditions.

KPG-818 is a small molecule modulator of CRBN E3 ubiquitin ligase complex CRL4-CRBN. In the Phase Ib/IIa clinical study in SLE patients (trial ID: NCT04643067) completed in the US, KPG-818 demonstrated promising efficacy and a favorable safety and tolerability profile.

About Kangpu Biopharmaceuticals

Kangpu Biopharmaceuticals, Ltd. is a clinical-stage company focused on the discovery and development of innovative molecular glue-based therapeutics for the treatment of autoimmune diseases, solid tumors, hematologic malignancies and inflammatory disorders. Kangpu has developed a robust pipeline of potential first-in-class and best-in-class drug candidates based on proprietary technology platforms, including NeoMIDES^®, gDACS^®, and X-SYNERGY^®.

For more information, please visit www.KangpuGroup.com

Media Contact: Florence Liu, [email protected] 

Source : Kangpu Completed Bridging Clinical Study of KPG-818 in China

The information provided in this article was created by Cision PR Newswire, our news partner. The author's opinions and the content shared on this page are their own and may not necessarily represent the perspectives of Thailand Business News.